UK's NICE recommends use of Halaven (eribulin) for locally advanced or metastatic breast cancer- Eisai

The National Institute of Health and Care Excellence (NICE) has recommended Halaven (eribulin), from Eisai, for the treatment of locally advanced or metastatic breast cancer in a Final Appraisal Determination published today. NICE has recommended Eribulin for the treatment of adults with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimen for advanced disease. Prior therapy may have included an anthracycline or a taxane, and capecitabine. Eribulin is the first breast cancer treatment to be recommended by NICE in nearly a decade.

Comment: Eribulin was first approved and launched in the UK in 2011 and marketing authorisation was extended for earlier use in advanced breast cancer from the European Commission on 3 July 2014. In November 2011, NICE gave final draft guidance not recommending Halaven for the treatment of locally-advanced or metastatic breast cancer in people whose disease has progressed after at least two chemotherapeutic regimens for advanced disease.